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Abstract
Past research with the Spontaneously Hypertensive Rat (SHR) model of Attention Deficit/
Hyperactivity Disorder showed that adolescent methylphenidate treatment enhanced cocaine abuse 
risk in SHR during adulthood. Acquisition of cocaine self-administration was faster, and cocaine 
dose-response functions were shifted upward under fixed-ratio and progressive ratio schedules 
compared to adult SHR that received adolescent vehicle treatment or to control strains that 
received adolescent methylphenidate treatment. The current study determined if extending 
treatment beyond adolescence would ameliorate long-term consequences of adolescent 
methylphenidate treatment on cocaine abuse risk in adult SHR. Treatments (vehicle or 1.5 
mg/kg/day oral methylphenidate) began on postnatal day 28. Groups of male SHR were treated 
with vehicle during adolescence and adulthood, with methylphenidate during adolescence and 
vehicle during adulthood, or with methylphenidate during adolescence and adulthood. The group 
receiving adolescent-only methylphenidate was switched to vehicle on P56. Cocaine self-
administration began on postnatal day 77, and groups receiving methylphenidate during 
adolescence and adulthood were treated either 1-hr before or 1-hr after daily sessions. At baseline 
under a fixed-ratio 1 schedule, cocaine self-administration (2 hr sessions; 0.3 mg/kg unit dose) did 
not differ among the four treatment groups. Under a progressive ratio schedule (4.5 hr maximum 
session length; 0.01 – 1.0 mg/kg unit doses), breakpoints for self-administered cocaine in SHR 
receiving the adult methylphenidate treatment 1-hr pre-session were not different from the vehicle 
control group. However, compared to the vehicle control group, breakpoints for self-administered 
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cocaine at the 0.3 and 1.0 mg/kg unit doses were greater in adult SHR that received adolescent-
only methylphenidate or received methylphenidate that was continued into adulthood and 
administered 1-hr post-session. These findings suggest that extending methylphenidate treatment 
beyond adolescence does not ameliorate explicitly the long-term consequences of adolescent 
methylphenidate treatment. Pre-session methylphenidate may mask temporarily the detection of an 
increase in cocaine self-administration following chronic methylphenidate treatment.
Keywords
Adolescence; Attention Deficit/Hyperactivity Disorder; Cocaine; Methylphenidate; Self-
administration; Spontaneously Hypertensive Rat
1. Introduction
Methylphenidate is a psychostimulant commonly prescribed for the management of 
Attention Deficit/Hyperactivity Disorder (ADHD) in children and teenagers. Although an 
early meta-analysis concluded that stimulant medication initiated in childhood is protective 
against substance use disorders (SUD) later in life (Wilens et al., 2003), the most recent 
meta-analysis and Multimodal Treatment Study concluded that stimulant treatment for 
ADHD initiated in childhood neither protects against nor increases risk of later SUD 
(Humphreys et al., 2013; Molina et al., 2013). Some evidence that ADHD medication 
initiation (methylphenidate in particular) during adolescence may have different long-term 
consequences for adult SUD than initiation in childhood is derived from research 
specifically analyzing age of treatment onset. One study (Mannuzza et al., 2008) excluded 
participants with conduct disorder and stratified children into age groups (6–7 vs. 8–12 
years) for methylphenidate treatment initiation (lasting 2–4 years). Participants developing 
adult SUD initiated treatment at a later age than those who never developed SUD, though 
antisocial personality disorder may have influenced this relationship (Mannuzza et al., 
2008). In another study, SUD risk in adulthood increased by a factor of 1.5 for every year 
older that childhood stimulant treatment began (Dalsgaard et al., 2014). A critical gap in the 
literature exists, however, regarding SUD in adults who began ADHD treatment as 
teenagers. Currently, ~20% of teens with ADHD in the United States receive a first 
diagnosis between ages 11–17, representing an estimated 700,000 people (National Survey 
of Children’s Health Database, 2011/12). Studying the long-term consequences of 
adolescent-onset methylphenidate treatment is important because stimulants can change the 
trajectory of neuronal development during adolescence (Andersen, 2005; Casey and Jones, 
2010).
Research using an animal model of ADHD would contribute to understanding the effects of 
methylphenidate treatment in newly diagnosed teenagers. The spontaneously hypertensive 
rat (SHR) is the most widely studied and validated animal model of ADHD (Russell, 2011). 
SHR exhibit frontostriatal neurocognitive deficits during adolescence and adulthood 
(Gauthier et al., 2014; Harvey et al., 2013; Kantak et al., 2008; Wells et al., 2010) and self-
administer greater amounts of cocaine and other drugs of abuse compared to control strains 
(Chen et al., 2012; dela Pena et al., 2011; Jordan et al., 2014; Marusich et al., 2011; 
Somkuwar et al., 2013a). These later findings are consistent with epidemiological studies 
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showing that having ADHD carries a 2–3 times greater risk of tobacco, cocaine and 
marijuana abuse by young adulthood (Lee et al., 2011). Additional preclinical studies 
demonstrated that adult SHR that had received adolescent methylphenidate treatment 
acquired cocaine self-administration more rapidly and exhibited upward shifts in cocaine 
dose-response functions under fixed-ratio (FR) and progressive ratio (PR) schedules 
compared to adult SHR that had received adolescent vehicle treatment and to control strains 
that had received adolescent methylphenidate treatment (Harvey et al., 2011). These 
findings suggest that adolescent methylphenidate treatment further enhanced cocaine abuse 
risk in adult SHR. In these past studies, methylphenidate treatment was discontinued at the 
end of adolescence, which was 3 weeks prior to the initiation of cocaine self-administration 
during adulthood. The current study tested the hypothesis that extending treatment beyond 
adolescence would ameliorate the long-term consequences of adolescent methylphenidate on 
cocaine abuse risk in adult SHR. This hypothesis is based on observations that 
methylphenidate treatment 2 hr before sessions does not increase cocaine choice behavior in 
adult ADHD patients compared to non-ADHD controls (Collins et al., 2006). However, 
methylphenidate pretreatment reduces cocaine binding at the dopamine transporter (DAT) 
(Berglund et al., 2013; Volkow et al., 1995), and this may have masked the effects of 
chronic methylphenidate treatment on cocaine self-administration in the adult ADHD 
patients. To test this hypothesis, rats receiving chronic methylphenidate from adolescence 
into adulthood were treated with methylphenidate either 1 hr before or 1 hr after daily 
cocaine self-administration sessions and the number of cocaine infusions were determined.
2. Materials and methods
Male SHR/NCrl rats (25 days old on arrival) were housed individually (08:00 h lights on, 
20:00 h lights off) and maintained in accordance with the NIH Guide for Care and Use of 
Laboratory Animals and the Boston University Institutional Animal Care and Use 
Committee. Figure 1 provides a graphical depiction of the experimental timeline and 
summary of procedures. Rats began treatment with 1.5 mg/kg (±)-methylphenidate 
hydrochloride (Sigma-Aldrich, St. Louis, MO) or water vehicle on postnatal day 28 (P28), 
the start of adolescence in rats (Spear, 2000). Treatments were administered via oyster 
crackers on Monday-Friday to mimic the clinical practices of oral dosing and medication-
free holidays on weekends for young patients with ADHD (Martins et al., 2004). A 1.5 
mg/kg/day dose of oral methylphenidate produces peak plasma concentrations between 9–36 
ng/ml in rats (Kuczenski and Segal, 2002), which is within peak plasma concentrations (8–
40 ng/ml) achieved in pediatric patients (Swanson et al., 1999). This dose of oral 
methylphenidate also is clinically relevant because it lacks locomotor activating effects 
(Gerasimov et al., 2000), preferentially increases dopamine and norepinephrine signaling in 
prefrontal cortex (Berridge et al., 2006), and has procognitive effects in SHR (Harvey et al., 
2013; Kantak et al., 2008). The amount of time to consume daily oyster crackers containing 
methylphenidate or vehicle averaged < 3 min. Groups of SHR were treated with vehicle 
during adolescence and adulthood (VEH/VEH; n=10), with methylphenidate during 
adolescence and vehicle during adulthood (MPH/VEH; n=8; 20 ± 0 total days of 
methylphenidate treatment), or with methylphenidate during adolescence and adulthood 
(MPH/MPH; n=15). The group receiving adolescent-only methylphenidate was switched to 
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vehicle treatment on P56. Rats receiving adolescent and adult methylphenidate were 
subdivided into two groups and treated with methylphenidate either 1-hr before (MPH/MPH 
1-hr Pre; n=8; 61 ± 3 total days of methylphenidate treatment) or 1-hr after (MPH/MPH 1-hr 
Post; n=7; 67 ± 2 total days of methylphenidate treatment) daily self-administration sessions 
that began on P77 (see below). Rats given vehicle during adulthood received treatment 1-hr 
after daily self-administration sessions.
On P67, catheters were surgically implanted into the right femoral vein under intraperitoneal 
ketamine (90 mg/kg) and xylazine (10 mg/kg) anesthesia. Surgery, post-surgical care and 
catheter maintenance were as previously described (Somkuwar et al., 2013a). 
Methylphenidate and vehicle treatments were suspended the day of and for three days 
following surgery to prevent interactions with drugs used during surgery and during post-
surgical care. Beginning on P75, rats were trained to lever press for 50 food pellets for two 
days. The average session lengths for the second food pellet session ranged from 29 ± 5 to 
36 ± 10 min, with response rates ranging from 1.43 ± 0.24 to 2.38 ± 0.56 responses/min, 
with no significant group differences. Self-administration training then began in daily 
(Monday–Friday) 2 hr sessions under an FR1 20-sec timeout schedule of cocaine delivery 
using a 0.3 mg/kg unit dose (expressed as the hydrochloride salt; National Institute on Drug 
Abuse Drug Supply Program, Bethesda, MD). The cocaine solution, chamber configuration 
and session contingencies were as described previously (Somkuwar et al., 2013a). Rats 
continued self-administration sessions under the FR 1 schedule for a minimum of 10 
sessions and until responses stabilized (<10% variation for 5 consecutive sessions and a ratio 
of 2:1 active to inactive lever responses). Under the FR 1 schedule, cocaine was limited to a 
maximum of 90 injections per 2 hr session to prevent accidental overdose (8 of 33 rats, 
equally represented in each treatment group, reached this threshold on 1–4 occasions early 
in training). Next, rats began training under a PR schedule (Loh and Roberts, 1990) using 
the 0.3 mg/kg cocaine unit dose for a minimum of 5 sessions and until breakpoints 
stabilized. This schedule involved a geometric increment in the number of lever presses 
required for each successive drug infusion (e.g., 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 
77, 95, 118, 145, 178, 219, 268, 328, 402, 492, 603, etc.). PR breakpoint was defined as the 
last FR completed when the session ended. Once PR breakpoints were stable, a range of 
cocaine unit doses (0.01, 0.1, 0.3 and 1.0 mg/kg) that included the training dose was 
substituted in descending order, with 2–3 sessions per dose. Sessions terminated when a rat 
failed to complete the current FR requirement within 60 min of the last cocaine infusion or 
4.5 hr had elapsed, whichever occurred first (3 of 33 rats reached the 4.5 hr threshold on 1–2 
occasions during PR training, and 5 of 33 rats reached this threshold on 1 occasion during 
PR testing with the 1.0 mg/kg unit cocaine dose). The number of active and inactive lever 
responses, cocaine infusions and PR breakpoints were recorded and analyzed. As all rats 
were initially trained to lever press for food pellets, sessions to acquire cocaine self-
administration were not analyzed. Valid assessment of acquisition of self-administration, as 
previously reported in SHR and control strains after adolescent methylphenidate treatment 
(Harvey et al., 2011), requires that rats are given no external inducements to lever press 
(e.g., prior lever press training for food pellets, food restriction or lever baiting). In the 
present study, response rates on the first and last FR 1 cocaine self-administration training 
sessions that followed food pellet training were similar across groups, with overall averages 
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of 0.87 ± 0.14 and 0.66 ± 0.04 responses/min, respectively. As anticipated of rats with prior 
lever press training, response rates under the FR 1 schedule of cocaine self-administration 
were not significantly different on the first and last sessions of training, and were 
significantly lower (p<0.001) than the response rate generated by food reinforcement under 
the FR 1 schedule (overall average of 1.81 ± 0.20 responses/min).
Baseline performance was defined as the last 5 training sessions under the FR 1 and PR 
schedules. Values were averaged for individual rats prior to statistical analysis. Also, values 
from the last 2 dose-testing sessions under the PR schedule were averaged for individual rats 
prior to statistical analysis. All dependent measures were analyzed by one-factor (treatment 
group) or two-factor (treatment group X dose) analysis of variance with repeated measures 
for dose, and by Dunnett’s t-tests that control for type-1 error and permit post-hoc 
comparisons of methylphenidate groups to the vehicle control group regardless of the 
outcome of the analysis of variance (Winer et al., 1991).
3. Results
At the FR1 baseline, active and inactive lever responses and cocaine infusions were not 
significantly different across treatment groups (Figure 2a and 2b). In contrast, under the PR 
schedule (Figure 3), baseline breakpoints differed among the four treatment groups (F[3, 29] 
= 2.8, p<0.05). Adult SHR treated with methylphenidate during adolescence and then 
receiving either vehicle during adulthood (MPH/VEH) or post-session methylphenidate 
during adulthood (MPH/MPH 1-hr Post) had higher breakpoints at baseline compared to the 
VEH/VEH control (p ≤ 0.04 and 0.03, respectively). Baseline breakpoints in the adult SHR 
treated with methylphenidate during adolescence and then receiving pre-session 
methylphenidate during adulthood (MPH/MPH 1-hr Pre) did not differ from the VEH/VEH 
control.
During PR testing with a range of cocaine unit doses, analyses of breakpoints revealed dose-
related (F[3,29] = 3.4, p ≤ 0.03) and treatment-related (F[3,87] = 97.9, p ≤ 0.001) differences 
as well as a trend for a treatment group X dose interaction (F[9,87] = 1.8, p ≤ 0.07). Overall, 
adult SHR receiving MPH/VEH or MPH/MPH 1-hr Post had higher breakpoints than the 
VEH/VEH control (p ≤ 0.02). The MPH/MPH 1-hr Pre and VEH/VEH groups did not differ. 
Dunnett’s analysis of treatment groups at each dose revealed that adult SHR with adolescent 
only methylphenidate (MPH/VEH) had higher breakpoints at the 0.3 (p ≤ 0.04) and 1.0 (p ≤ 
0.001) mg/kg cocaine doses compared to the VEH/VEH control (Figure 4a). 
Methylphenidate treatment continued into adulthood and administered post-session 
(MPH/MPH 1-hr Post) maintained these elevated breakpoints (p ≤ 0.05 and p ≤ 0.001, 
respectively, compared to the VEH/VEH control). When methylphenidate treatment was 
continued and administered pre-session (MPH/MPH 1-hr Pre), breakpoints were not 
different from the VEH/VEH control at any dose. Analysis of active lever responses during 
cocaine dose-response testing also revealed dose-related (F[3,87] = 98.7, p ≤ 0.001) and 
treatment-related (F[3,29] = 4,0, p ≤ 0.02) differences as well as a treatment group X dose 
interaction (F[9,87] = 2.2 p ≤ 0.03). Overall, adult SHR receiving MPH/VEH or MPH/MPH 
1-hr Post emitted more active lever responses than the VEH/VEH control (p ≤ 0.01). 
Dunnett’s analysis of treatment groups at each dose revealed these differences were 
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significant at the 0.3 and 1.0 mg/kg cocaine doses (p ≤ 0.04 and 0.001, respectively; Figure 
4b). Adult SHR receiving MPH/MPH 1-hr Pre did not differ from the VEH/VEH control at 
any dose for active lever responses. Analysis of inactive lever responses revealed only dose-
related differences (F[3,87] = 4.9, p ≤ 0.003), with the highest cocaine dose associated with 
more inactive lever responses than the lowest cocaine dose, overall (p ≤ 0.001). Inactive 
lever responses did not differ across treatment groups at any dose (Figure 4b). Lastly, 
analysis of infusions earned during cocaine dose-response testing revealed dose-related 
(F[3,87] = 197.8, p ≤ 0.001) and a trend for treatment-related (F[3,29] = 2.6, p ≤ 0.07) 
differences. Dunnett’s analysis of treatment groups at each dose revealed that adult SHR in 
the MPH/VEH or MPH/MPH 1-hr Post groups earned more infusions at the 0.3 and 1.0 
mg/kg cocaine doses compared to the VEH/VEH control (p ≤ 0.04 and 0.02, respectively; 
Figure 4c). The MPH/MPH 1-hr Pre group did not differ from the VEH/VEH control at any 
dose.
4. Discussion
Previous research has demonstrated that 1.5 mg/kg/day oral methylphenidate, administered 
during adolescence and then discontinued, increases the motivation to self-administer 
cocaine in adult SHR (Harvey et al., 2011). PR breakpoints (last FR completed) were 
consistently higher across cocaine unit doses (0.01 – 1.0 mg/kg) in methylphenidate-treated 
SHR (maximum breakpoint ~200) compared to vehicle-treated SHR (maximum breakpoint 
~100) or methylphenidate-treated Wistar-Kyoto and Wistar controls (maximum breakpoint 
~40). The current study replicated the dose-related performance of SHR, with PR 
breakpoints reaching a maximum of ~225 after adolescent methylphenidate treatment and a 
maximum of ~125 after vehicle treatment. Historically, descending- (Harvey et al., 2011) 
and random-order (Brebner et al., 1999; McGregor et al., 1996) dose tests under a PR 
schedule in untreated Wistar rats produce overlapping breakpoints (last FR completed) 
across a range of cocaine doses, suggesting that the in the present study, dose order was not 
a variable influencing the results. As these findings suggest an unfavorable consequence of 
adolescent methylphenidate treatment on later cocaine abuse risk in rats with an ADHD 
phenotype, we explored whether extending methylphenidate treatment beyond adolescence 
would be protective in SHR. This is important because as many as 65% of adolescents with 
ADHD continue to meet criteria for the disorder in adulthood, and more than half stop 
taking ADHD medications by age 18 (McCarthy et al., 2012). Notably, past studies have 
shown that methylphenidate treatment either reduced or did not modify cocaine use in adult 
ADHD patients (Collins et al., 2006; Levin et al., 2007). In rhesus monkeys and outbred 
rats, pretreatment with oral methylphenidate at doses in the therapeutic range either reduced 
or did not modify cocaine self-administration as well (Czoty et al., 2013; Hiranita et al., 
2009; Thanos et al., 2007). In the present study, methylphenidate treatment begun in 
adolescence and given 1-hr prior to daily sessions in adult SHR did not modify PR 
breakpoints for cocaine. In contrast, methylphenidate treatment begun in adolescence and 
given 1-hr after daily sessions in adult SHR increased PR breakpoints to the same degree as 
adolescent-only methylphenidate treatment. Thus, the timing of daily methylphenidate 
treatment relative to cocaine access in adulthood is critical for detecting an increase in 
cocaine abuse risk in SHR. Importantly, group differences under the PR schedule were not 
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dependent on FR 1 baseline performance, as cocaine self-administration behavior was 
similar across groups under the less demanding FR1 schedule.
The different effects of pre- and post-session methylphenidate may relate to interactions of 
methylphenidate and cocaine at the dopamine transporter (DAT), which is a critically 
important target for the reinforcing effects of cocaine (Ramamoorthy et al., 2010) and for 
ADHD symptom relief (Krause et al., 2005). Among their multiple mechanisms, 
methylphenidate and cocaine each bind to DAT and inhibit the reuptake of dopamine 
(Zahniser and Sorkin, 2004). Our past research has shown that 1.5 mg/kg/day oral 
methylphenidate, administered during adolescence and then discontinued, increased Vmax 
for dopamine uptake at DAT (DAT function) in medial prefrontal cortex (mPFC) of adult 
SHR, but not in Wistar-Kyoto and Wistar controls (Somkuwar et al., 2013b). Increased DAT 
function in SHR would lead to lower basal dopamine tone, a condition that results in 
abnormally high phasic dopamine responses (Grace, 2001). As cocaine is directly self-
administered into the mPFC (Goeders and Smith, 1983; 1986), such a mechanism involving 
the mPFC may contribute to the increased efficacy and motivating influence of self-
administered cocaine in adult SHR treated with methylphenidate during adolescence 
(Harvey et al., 2011). As a dopamine reuptake inhibitor, methylphenidate administered pre-
session may temporarily interfere with increased mPFC DAT function that is normally 
observed when methylphenidate is not onboard, and in this way, mask detection of an 
increase in the reinforcing effects of cocaine in adult SHR. DAT inhibition by 
methylphenidate pretreatment also reduces cocaine binding at DAT (Berglund et al., 2013; 
Volkow et al., 1995), which could lessen the impact of self-administered cocaine. Post-
session methylphenidate, like discontinued methylphenidate, may expose the increase in 
mPFC DAT function and maintain the enhanced motivation to self-administer cocaine in 
adult SHR.
In rats, therapeutic doses of orally administered methylphenidate produce peak plasma 
concentrations ~15 min after administration, with a half-life of ~1 hr (Aoyama et al., 1990; 
Kuczenski & Segal 2002). Within cortical sites, peak changes in BOLD magnetic resonance 
signals in rats are attained at 45–90 min following methylphenidate treatment (Easton et al., 
2009). Although in the present study the once daily dosing with methylphenidate does not 
result in steady state plasma levels in rats, the above pharmacokinetic and imaging results 
suggest that significant amounts of methylphenidate were still present and neurally active at 
the start of cocaine self-administration sessions in SHR treated 1 hr before, but not 1 hr after 
the sessions. Methylphenidate pharmacokinetics in pediatric patients, who typically receive 
either an immediate release (2–3 times daily) or an extended release (once daily) 
formulation, are different than in rats receiving a once daily dose. In pediatric patients, 
plasma concentrations peak later (~2 hr) and the half-life and duration of action are longer 
(~6–12 hr) than in rats (Coghill et al., 2013; Shaywitz et al., 1982; Swanson and Volkow, 
2003). Thus, if steady state plasma levels of methylphenidate had been achieved in the SHR 
in the current study, as is standard for ADHD patients, then increases in DAT function and 
cocaine abuse risk may not have occurred. However, results show that in rats with steady 
state plasma levels (achieved via 40 intravenous injections of 0.56 mg/kg methylphenidate 
over a 6 hr period for 5 days), an increase in striatal DAT function was found 24 hr later 
(when methylphenidate was not onboard) compared to untreated controls (Calipari et al., 
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2014). These findings suggest that the long-term consequences of adolescent 
methylphenidate treatment on DAT function do not depend on achieving steady state plasma 
levels. Initiating methylphenidate treatment in SHR during adolescence and determining 
behavior in adulthood when methylphenidate was not onboard may be critical factors for 
observing increases in DAT function and cocaine abuse risk. Consistent with this view are 
clinical findings showing the later that twice-daily methylphenidate treatment begins in 
pediatric ADHD patients, the greater the risk of developing SUD during adulthood 
(Mannuza et al., 2008).
5. Conclusions
Every animal model of neuropsychiatric disease has limitations (Nestler and Hyman, 2010). 
Nonetheless, SHR exhibit behavioral and cognitive deficits (Kantak et al., 2008; Russell, 
2011; Sagvolden et al., 2005) as well as neurochemical and genetic differences (e.g., Mill et 
al., 2005 and Roessner et al., 2010) similar to those observed in ADHD. The SHR model of 
ADHD can help address clinically relevant questions concerning ADHD and SUD more 
appropriately than research limited to animal models that do not exhibit an ADHD 
phenotype (e.g., Adriani et al., 2006; Andersen et al., 2002; Brandon et al., 2001; Carlezon 
et al., 2003; Ferguson and Boctor, 2010; Gill et al., 2012; Thanos et al., 2007). Thus, the 
SHR model may provide novel insights concerning cocaine abuse risk subsequent to 
methylphenidate treatment for ADHD initiated during adolescence and extending into 
adulthood.
Specifically, discontinuation of adolescent methylphenidate treatment for the management 
of ADHD may place teens at greater risk of abusing cocaine in adulthood, i.e., at a risk 
beyond that associated with ADHD alone. The idea of extending methylphenidate treatment 
beyond adolescence to avoid a greater risk of cocaine abuse might only be valid if patients 
strictly adhere to their medication regimen. However, adherence is irregular among adults 
with ADHD who oftentimes miss or delay taking their medication (Caisley and Muller, 
2012). If adult patients are non-compliant with their medication and cocaine is sampled 
when methylphenidate is not onboard, then cocaine may have greater reinforcing effects and 
higher potential for abuse. Our results in SHR advocate for the design of informative clinical 
studies that specifically probe the long-term consequences of adolescent-onset 
methylphenidate treatment on adult SUD. Participants should be stratified into groups 
according to the developmental stage at which treatment began, the specific medication 
prescribed, and the length of treatment. Continued research with the SHR animal model of 
ADHD contributes to this understudied public health concern in adolescent patients by 
elucidating the behavioral and neural mechanisms that account for greater cocaine abuse risk 
following adolescent-initiated methylphenidate treatment.
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Highlights
• Adolescent methylphenidate treatment increases cocaine abuse risk in adult 
SHR
• Extending methylphenidate treatment beyond adolescence is not protective
• Treatment prior to cocaine access may mask the effect of chronic 
methylphenidate
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Figure 1. 
Graphical depiction of the experimental timeline and summary of procedures Abbreviations: 
postnatal day (P), fixed ratio schedule of reinforcement (FR), progressive ratio schedule of 
reinforcement (PR).
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Figure 2. 
Baseline responding for self-administered cocaine under an FR1 schedule in adult SHR 
receiving vehicle during adolescence and adulthood (VEH/VEH), methylphenidate during 
adolescence and vehicle during adulthood (MPH/VEH), methylphenidate during 
adolescence and adulthood, with adult treatment occurring 1-hr before self-administration 
sessions (MPH/MPH 1-hr Pre), or methylphenidate during adolescence and adulthood, with 
adult treatment occurring 1-hr after self-administration sessions (MPH/MPH 1-hr Post). 
Values are the mean ± S.E.M. active and inactive lever responses (a) and infusions earned 
(b).
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Figure 3. 
Baseline breakpoints for self-administered cocaine under the PR schedule in adult SHR 
receiving vehicle during adolescence and adulthood (VEH/VEH), methylphenidate during 
adolescence and vehicle during adulthood (MPH/VEH), methylphenidate during 
adolescence and adulthood, with adult treatment occurring 1-hr before self-administration 
sessions (MPH/MPH 1-hr Pre), or methylphenidate during adolescence and adulthood, with 
adult treatment occurring 1-hr after self-administration sessions (MPH/MPH 1-hr Post). 
Values are the mean ± S.E.M. last FR completed. * p ≤ 0.04 compared to the VEH/VEH 
control.
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Figure 4. 
Cocaine dose-response functions under the PR schedule in adult SHR receiving vehicle 
during adolescence and adulthood (VEH/VEH), methylphenidate during adolescence and 
vehicle during adulthood (MPH/VEH), methylphenidate during adolescence and adulthood, 
with adult treatment occurring 1-hr before self-administration sessions (MPH/MPH 1-hr 
Pre), or methylphenidate during adolescence and adulthood, with adult treatment occurring 
1-hr after self-administration sessions (MPH/MPH 1-hr Post). Values are mean ± S.E.M. 
breakpoints (a), active (white symbols) and inactive (black symbols) lever responses (b), and 
infusions earned (c). * p ≤ 0.05 compared to the VEH/VEH control.
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